Here are the key facts about TMDX (TransMedics Group, Inc.) based on the provided context:
### Recent Developments & Performance
1. Financial Growth (2023-2024):
– Revenue increased 93% year-over-year in Q1 2024, reaching $76.7M .
– Full-year 2024 revenue guidance: $340M–$360M (implies ~50% YoY growth) .
2. Profitability Progress:
– Gross margin improved to 71% in Q1 2024 (up from 63% YoY) .
– Not yet GAAP profitable, but EBITDA turned positive in 2023 .
3. Commercial Expansion:
– Scaling its National OCS Program (Organ Care System) for heart, lung, and liver transplants .
– FDA approvals for OCS Heart and Lung systems driving adoption .
4. Market Opportunity:
– Addresses the global donor organ shortage (U.S. transplant waitlist: ~100,000 patients) .
– Competes with traditional cold-storage methods; clinical data shows superior outcomes with OCS .
### Risks & Challenges
– High R&D/CAPEX costs: Scaling manufacturing and logistics is capital-intensive .
– Reimbursement hurdles: Insurance coverage for OCS procedures remains uneven .
– Competition: Emerging perfusion technologies from rivals like Paragonix .
### Upcoming Catalysts
– FDA decision on OCS Liver (expected late 2024) .
– International expansion (Europe/Canada) .
Would you like deeper analysis on any specific aspect (e.g., cash burn, clinical data)? I can provide additional context if available. For investment decisions, consult SEC filings and a financial advisor.